← Back to Search

Nicotine Replacement Therapy

Nicotine Replacement Therapy for Smoking Cessation (CAN-DOSE Trial)

Phase 2
Waitlist Available
Led By Amanda Palmer
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18yrs +
Daily nicotine-containing e-cigarette user (25+ days per previous month)
Must not have
Medical conditions contraindicated to NRT use (including pregnancy, past month myocardial infarction, current cardiac arrhythmia, current angina, uncontrolled vascular disease, or medical conditions in which consumption of phenylalanine is contraindicated)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28, day 56
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if nicotine patches and lozenges can help people who both smoke and vape to quit. It compares different doses to see which works best. The goal is to find an effective way to help dual users stop using tobacco products. Nicotine patches and lozenges have been studied extensively as aids to help people stop smoking, with various studies indicating their potential effectiveness.

Who is the study for?
The CAN-DOSE study is for adults over 18 who use nicotine e-cigarettes daily and smoke cigarettes weekly, wanting to quit both within a month. They must be willing to use nicotine replacement therapy (NRT) and have no medical conditions that make NRT unsafe, like recent heart issues or pregnancy.
What is being tested?
This study tests whether using nicotine patches and lozenges can help people stop smoking and vaping. It compares the effectiveness of regular versus higher doses of these medications in aiding cessation.
What are the potential side effects?
Possible side effects from the nicotine patch and lozenge include skin irritation at the patch site, sleep problems, headache, nausea, dizziness, racing heartbeat, muscle pain or stiffness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I use nicotine e-cigarettes daily.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have heart issues, uncontrolled vascular disease, or conditions affected by phenylalanine.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28, day 56
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28, day 56 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Days of dual use abstinence
Secondary study objectives
Feasibility/Acceptability
Reduction
Safety

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Active Control
Group I: Arm AActive Control1 Intervention
21mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
Group II: Arm BActive Control1 Intervention
21mg patch + 14mg patch qd + 4mg lozenge prn minimum of 5 \& \[up to 30 per day\]
Group III: Arm CActive Control1 Intervention
2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Nicotine Replacement Therapy (NRT) helps smoking cessation by delivering controlled doses of nicotine to the body, reducing withdrawal symptoms and cravings without the harmful chemicals found in tobacco smoke. This controlled nicotine delivery can be achieved through patches, lozenges, and nasal sprays. Understanding these mechanisms is crucial for patients as it shows how NRT can manage physical dependence on nicotine, thereby increasing the likelihood of successfully quitting smoking.
Nicotine Replacement Therapy: An Overview.The natural history of efforts to stop smoking: a prospective cohort study.Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms.

Find a Location

Who is running the clinical trial?

American Cancer Society, Inc.OTHER
231 Previous Clinical Trials
109,504 Total Patients Enrolled
Medical University of South CarolinaLead Sponsor
971 Previous Clinical Trials
7,399,151 Total Patients Enrolled
Amanda PalmerPrincipal InvestigatorMedical University of South Carolina
~24 spots leftby Nov 2025